Health
New VERTIS-CV data: Kidney function preserved with ertugliflozin in type 2 diabetes – Healio
New exploratory analyses show treatment with the SGLT2 inhibitor ertugliflozin reduced risk for worsening kidney function, dialysis or renal death among adults with type 2 diabetes compared with placebo.In prespecified exploratory analyses presented at the vi…
Source/Disclosures
Source: Cherney D. VERTIS-CV Outcome. Presented at: EASD Annual Meeting; Sept. 21-25, 2020 (virtual meeting).
Disclosures:
Merck and Pfizer sponsored VERTIS-CV. Cannon reports he has received research grants or honoraria from Aegerion, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, Boehringer Ingelheim, Bristol-Myers Squibb, Corvidia, Daiichi Sankyo, HLS Therapeutics, Innovent, Janssen, Kowa, Merck, Pfizer and Sanofi. Cherney reports he has received consultant f…
-
Business4 hours agoSoaring one day, plunging the next. Why is the ASX 200 on a rollercoaster?
-
Business11 hours agoHow I’d build a $100,000 ASX portfolio from scratch
-
Noosa News6 hours agoBrisbane man Benjamin Holt speaks out about teen who allegedly organised Airbnb party that led to his house being trashed
-
General24 hours agoTrump’s tariffs: a bad idea executed badly